Novel single nucleotide polymorphisms in interleukin 6 affect tacrolimus metabolism in liver transplant patients.

ABSTRACT:

Background

Tacrolimus is the first-line immunosuppressant after organ transplantation. It is mainly metabolized by cytochrome P450, family 3, subfamily A (CYP3A) enzymes, but there are large individual differences in metabolism. Interleukin 6 (IL6) has been shown to cause a pan-suppression of mRNA levels of ten major CYP enzymes in human hepatocyte cultures. IL6 has been shown to provide hepatoprotection in various models of liver injury. Rs1800796 is a locus in the IL6 gene promoter region which regulates cytokine production. We speculated that IL6 rs1800796 polymorphisms may lead to individual differences in tacrolimus metabolism by affecting CYP3A enzymes levels and liver function after liver transplantation.

Methodology/principal findings

Ninety-six liver transplant pati

SUBMITTER: Chen D 

PROVIDER: S-EPMC3753270 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature